1921
Volume 100, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

A subset of multibacillary (MB) leprosy patients manifest with clinical “nonresponsiveness” to the fixed-duration, World Health Organization multidrug therapy MB regimen (WHO-MDT-MBR). The aim of this retrospective study was to assess the effectiveness and safety of alternate anti-leprosy therapy (ALT) in such patients. This is an analysis of patients’ records, registered in the leprosy clinic of our institute over a period of 6 years (2010–2015). The criteria for inadequate response/nonresponsiveness to treatment were as follows: 1) persistent/new lesions after completing ≥ 12 months of WHO-MDT-MBR (isolated reactions were ruled out histopathologically) and 2) persistent positive/increasing value of the morphological index (MI) and a 2 log increase in the bacteriological index (BI) after ≥ 12 months of WHO-MDT-MBR. Such cases were treated with ALT consisting of minocycline, clofazimine, and ofloxacin (24 months). Of 556 patients registered during the study period, 40.3% (224) were slit-skin smear (SSS) positive and 59.7% (332) were SSS negative. Of all, 35 patients (6.3%) satisfied the criteria for clinical nonresponsiveness. Of 224 SSS-positive patients, these 35 patients amounted to 15.6%. The mean BI and MI of these patients after completion of ≥ 12 months of WHO-MDT-MBR were 5.3 ± 0.6 and 14 ± 6.8%, respectively. After 6 months of treatment with ALT, MI became negative (0) in all these patients. After completion of ALT, the mean BI and MI became 1.7 ± 0.7 and 0%, respectively ( < 0.0001). There were 16 patients with corticosteroid-dependent recurrent/chronic erythema nodosum leprosum, who had excellent response with significant reduction in the number of reactional episodes and mean dose of prednisolone required ( < 0.0001). No serious adverse effects were noted. We conclude that ALT is safe and effective in the management of MB leprosy patients who are nonresponsive to 12 months of WHO-MDT-MBR.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0256
2018-10-08
2020-10-01
Loading full text...

Full text loading...

/deliver/fulltext/14761645/100/1/tpmd180256.html?itemId=/content/journals/10.4269/ajtmh.18-0256&mimeType=html&fmt=ahah

References

  1. Smith CS, Aerts A, Saunderson P, Kawuma J, Kita E, Virmond M, 2017. Multidrug therapy for leprosy: a game changer on the path to elimination. Lancet Infect Dis 17: e293e297.
    [Google Scholar]
  2. World Health Organization, 2017. Global leprosy update, 2016: accelerating reduction of disease burden. Wkly Epidemiol Rec 92: 501519.
    [Google Scholar]
  3. Liu D et al., 2015. Drug resistance in Mycobacterium leprae from patients with leprosy in China. Clin Exp Dermatol 40: 908911.
    [Google Scholar]
  4. Contreras Mejia Mdel C, Porto Dos Santos M, Villarouco da Silva GA, da Motta Passos I, Naveca FG, Souza Cunha Mda G, Moraes MO, de Paula L, 2014. Identification of primary drug resistance to rifampin in Mycobacterium leprae strains from leprosy patients in Amazonas state, Brazil. J Clin Microbiol 52: 43594360.
    [Google Scholar]
  5. Lavania M et al., 2014. Drug resistance patterns in Mycobacterium leprae isolates from relapsed leprosy patients attending the leprosy mission (TLM) hospitals in India. Lepr Rev 85: 177185.
    [Google Scholar]
  6. Lavania M, Nigam A, Turankar RP, Singh I, Gupta P, Kumar S, Sengupta U, John AS, 2015. Emergence of primary drug resistance to rifampicin in Mycobacterium leprae strains from leprosy patients in India. Clin Microbiol Infect 21: e85e86.
    [Google Scholar]
  7. World Health Organization, 2010. WHO Expert Committee on Leprosy: Eighth Report. Report No.: WHO Technical Report Series; 968. Geneva, Switzerland: WHO.
    [Google Scholar]
  8. National Leprosy Eradication Programme, 2016. NLEP—Progress Report for the Year 2015–16. New Delhi, India: Central Leprosy Division, DGHS, Govt of India.
    [Google Scholar]
  9. Gupta UD, Katoch K, Singh HB, Natrajan M, Katoch VM, 2005. Persister studies in leprosy patients after multi-drug treatment. Int J Lepr Other Mycobact Dis 73: 100104.
    [Google Scholar]
  10. Shetty VP, Khambati FA, Ghate SD, Capadia GD, Pai VV, Ganapati R, 2010. The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; part 3—Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids vs. MDT alone, assessed at 6 months post-release from 12 months MDT. Lepr Rev 81: 4158.
    [Google Scholar]
  11. Sharma A, Sharma VK, Rajwanshi A, Das A, Kaur I, Kumar B, 1999. Presence of M. leprae in tissues in slit skin smear negative multibacillary (MB) patients after WHO-MBR. Lepr Rev 70: 281286.
    [Google Scholar]
  12. Lemaster JW, Shwe T, Butlin CR, Roche PW, 2001. Prediction of “highly skin smear positive” cases among MB leprosy patients using clinical parameters. Lepr Rev 72: 2328.
    [Google Scholar]
  13. Girdhar BK, Girdhar A, Kumar A, 2000. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr Rev 71: 144153.
    [Google Scholar]
  14. Jamet P, Ji B, 1995. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group. Int J Lepr Other Mycobact Dis 63: 195201.
    [Google Scholar]
  15. Dogra S, Sendhil Kumaran MS, Narang T, Radotra BD, Kumar B, 2013. Epidemiological characteristics and clinical outcome in multibacillary leprosy patients treated with 12 months WHO MDT-MBR at a referral hospital in northern India: a retrospective analysis of 730 patients. Lepr Rev 84: 6575.
    [Google Scholar]
  16. Garrido-Mesa N, Zarzuelo A, Galvez J, 2013. Minocycline: far beyond an antibiotic. Br J Pharmacol 169: 337352.
    [Google Scholar]
  17. Dalhoff A, Shalit I, 2003. Immunomodulatory effects of quinolones. Lancet Infect Dis 3: 359371.
    [Google Scholar]
  18. Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R, 2012. Clofazimine: current status and future prospects. J Antimicrob Chemother 67: 290298.
    [Google Scholar]
  19. Narang T, Arshdeep, Dogra S, 2016. Minocycline in leprosy patients with recent onset clinical nerve function impairment. Dermatol Ther 30: e12404.
    [Google Scholar]
  20. Narang T, Sawatkar GU, Kumaran MS, Dogra S, 2015. Minocycline for recurrent and/or chronic erythema nodosum leprosum. JAMA Dermatol 151: 10261028.
    [Google Scholar]
  21. Maia MV, Cunha Mda G, Cunha CS, 2013. Adverse effects of alternative therapy (minocycline, ofloxacin, and clofazimine) in multibacillary leprosy patients in a recognized health care unit in Manaus, Amazonas, Brazil. An Bras Dermatol 88: 205210.
    [Google Scholar]
  22. A Guide for Surveillance of Antimicrobial Resistance in Leprosy, 2017 Update. Geneva, Switzerland: WHO. Available at: www.who.int/lep/resources/9789290226192/en/. Accessed August 20, 2018.
    [Google Scholar]
  23. Odinsen O, Nilson T, Humber DP, 1986. Viability of Mycobacterium leprae: a comparison of morphological index and fluorescent staining techniques in slit-skin smears and M. leprae suspensions. Int J Lepr Other Mycobact Dis 54: 403408.
    [Google Scholar]
  24. Mahajan VK, 2013. Slit-skin smear in leprosy: lest we forget it! Indian J Lepr 85: 177183.
    [Google Scholar]
  25. Lastória JC, de Almeida TSC, Putinatti MSMA, Padovani CR, 2018. Effectiveness of the retreatment of patients with multibacillary leprosy and episodes of erythema nodosum leprosum and/or persistent neuritis: a single-center experience. Bras Dermatol 93: 181184.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0256
Loading
/content/journals/10.4269/ajtmh.18-0256
Loading

Data & Media loading...

  • Received : 25 Mar 2018
  • Accepted : 07 Sep 2018
  • Published online : 08 Oct 2018
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error